Formula Grant R43PS005271

The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $884,453 Project Grant to Brigham & Women's Hospital Inc. to develop a rapid, cost-effective point-of-care (POC) diagnostic test for Hepatitis C Virus (HCV) detection. The 5-year project, which commenced on November 22, 2024, aims to create a highly sensitive and specific HCV antigen (Ag) testing solution that can streamline...

This Project Grant award, totaling $354,570.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award aims to develop a cost-effective and user-friendly point-of-care (POC) diagnostic tool, employing a novel "CamoChip" technology, for highly sensitive and multiplex testing of biomarkers related to HIV/HBV co-infection. The key products and services to be delivered under...

This $575,356 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to The Trustees of Columbia University's Health Sciences Division on August 8, 2025. The funding supports the development of a rapid, multiplexed RT-PCR diagnostic for detecting hepatitis C virus (HCV) infection directly from whole blood samples. The proposed approach leverages plasmonic-based...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $306,872 to Cellia Science, Inc. to develop a rapid, point-of-care diagnostic tool for Spontaneous Bacterial Peritonitis (SBP), a severe complication of chronic liver disease. The project aims to integrate microfluidic-based sample preparation and advanced algorithm-driven cell classification to enable on-the-spot cell counting in ascitic...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $776,341 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Illinois on September 16, 2025. The purpose of this grant is to develop a microfluidic cartridge, molecular biology method, biosensor, and detection instrument that can simultaneously detect HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV) viral loads from a minimal 100 μL whole blood sample. This...

This $743,651 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to validate the use of plasma cell-free RNA (cfRNA) as a biomarker for the diagnosis of tuberculosis (TB) and monitoring of treatment. The grant will support the validation of cfRNA signatures in a large patient cohort of 1,378 adults across five countries, and the comparison of cfRNA diagnostic accuracy against...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $295,895 to Ricovr Healthcare Inc. to develop a rapid, low-cost, point-of-care (POC) diagnostic platform for quantitative measurement of placental growth factor (PlGF) to predict and detect pre-eclampsia. The goal is to create an objective, affordable POC tool to improve the clinical diagnosis and monitoring of pre-eclampsia, which...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $272,133 Project Grant under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to Rutgers, The State University of New Jersey to develop a rapid antigen test for diagnosing active hepatitis C virus (HCV) infection. The goal is to create a low-cost, instrument-free test that can accelerate diagnosis and linkage to care, as current treatments can effectively cure HCV but most infected...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), Catalog of Federal Domestic Assistance (CFDA) 93.855 Allergy and Infectious Diseases Research program, aims to inform the development of a simple, highly sensitive and specific, non-sputum-based point-of-care test (POCT) for tuberculosis (TB) diagnosis. The $850,711 award to Albert Einstein College of Medicine, located in Bronx, NY, will support the investigation of a panel of six monoclonal...

This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), provides $309,974 to support the development of a novel, low-cost device called LIVERscope. The LIVERscope device uses advanced magnetic resonance (MR) technology to noninvasively estimate quantitative biomarkers of nonalcoholic fatty liver disease (NAFLD), including liver...